Program
Febuxostat
Also written as “Febuxostat XR”, “Febuxostat 40 mg” and “Febuxostat 80 mg”.
Its studies are mostly in Gout · Hyperuricemia · Tumor Lysis Syndrome · Polycystic Kidney, Autosomal Dominant · Cardiovascular Diseases, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 180 open or running | phase 4since Jan 7, 2013 | Jan 29, 2005 | none ahead |
| Menarini Group | 30 open or running | phase 4since Jul 7, 2015 | Nov 7, 2012 | none ahead |
| AstraZeneca | 20 open or running | phase 2since Sep 19, 2014 | Jun 18, 2013 | none ahead |
| SK Chemicals | 20 open or running | phase 3since Jan 12, 2009 | Jan 12, 2009 | none ahead |
| Astellas Pharma | 10 open or running | phase 3since Nov 27, 2012 | Nov 27, 2012 | none ahead |
| Getz Pharma | 10 open or running | phase 4since Nov 2, 2015 | Nov 2, 2015 | none ahead |
| Pharmtechnology | 10 open or running | phase 1since Apr 15, 2019 | Apr 15, 2019 | none ahead |
Also a collaborator on its studies: altasciences-company-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Jan 29, 2005.
- Nov 7, 2012Menarini Group's first study: phase 3 study in Tumor Lysis SyndromeNew to Menarini GroupMenarini Group · NCT01724528 · 346 enrolled
- Nov 27, 2012Astellas Pharma's first study: phase 3 study in GoutNew to Astellas PharmaAstellas Pharma · NCT01736514 · 109 enrolled · Taiwan
- Jan 7, 2013Phase 4 study in Coronary Artery DiseaseTakeda · NCT01763996 · 30 enrolled · United States
- Jun 18, 2013AstraZeneca's first study: phase 1 study in HealthyNew to AstraZenecaAstraZeneca · NCT01883167 · 21 enrolled · United States
- Apr 29, 2014Phase 2 study in GoutTakeda · NCT02128490 · 189 enrolled · United States
- May 13, 2014Phase 3 study in GoutTakeda · NCT02139046 · 1,790 enrolled · United States
- Sep 19, 2014Phase 2 study in GoutAstraZeneca · NCT02246673 · 64 enrolled · United States
- Feb 22, 2015Phase 1 study in GoutTakeda · NCT02374164 · 36 enrolled · United States
- Mar 3, 2015Phase 1 study in Healthy VolunteersTakeda · NCT02382640 · 36 enrolled · United States
- Jul 7, 2015Phase 4 study in GoutMenarini Group · NCT02500641 · 196 enrolled · Germany, Italy, Netherlands and more
- Jul 20, 2015Phase 1 study in Healthy VolunteersTakeda · NCT02504320 · 78 enrolled · United States
- Nov 2, 2015Getz Pharma's first study: phase 4 study in HyperuricemiaNew to Getz PharmaGetz Pharma · NCT02600780 · 50 enrolled · Pakistan
- May 29, 2018Phase 2 study in Tumor Lysis SyndromeMenarini Group · NCT03605212 · 30 enrolled · Bulgaria, Hungary, Italy and more
- Apr 15, 2019Pharmtechnology's first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT03918551 · 50 enrolled · Canada
TargetBeta
“Xanthine dehydrogenase inhibitor”ChEMBL 37, by rule
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03918551Bioequivalence · Canada | 1 | Completed | Pharmtechnology | Jun 6, 2019 | 50 |
| NCT03605212Tumor Lysis Syndrome · Bulgaria, Hungary, Italy and more | 2 | Terminated | Menarini Group | Jul 25, 2018 | 30 |
| NCT02600780Hyperuricemia · Pakistan | 4 | Completed | Getz Pharma | Dec 2014 | 50 |
| NCT02504320Healthy Volunteers · United States | 1 | Completed | Takeda | Sep 2015 | 78 |
| NCT02500641Gout · Germany, Italy, Netherlands and more | 4 | Completed | Menarini Group | May 10, 2017 | 196 |
| NCT02382640Healthy Volunteers · United States | 1 | Completed | Takeda | May 2015 | 36 |
| NCT02374164Gout · United States | 1 | Completed | Takeda | Mar 2015 | 36 |
| NCT02246673Gout · United States | 2 | Completed | AstraZeneca | Jul 2015 | 64 |
| NCT02139046Gout · United States | 3 | Completed | Takeda | Nov 2015 | 1,790 |
| NCT02128490Gout · United States | 2 | Completed | Takeda | Sep 2015 | 189 |
| NCT01883167Healthy · United States | 1 | Completed | AstraZeneca | Sep 2013 | 21 |
| NCT01763996Coronary Artery Disease · United States | 4 | Completed | Takeda | Mar 2015 | 30 |
| NCT01736514Gout · Taiwan | 3 | Completed | Astellas Pharma | Feb 2012 | 109 |
| NCT01724528Tumor Lysis Syndrome | 3 | Completed | Menarini Group | Oct 2013 | 346 |
| NCT01563432Gout · Korea, Republic of | 1 | Completed | SK Chemicals | Feb 2012 | 30 |
| NCT01549977Angina Pectoris · United States | 2 | Terminated | Takeda | Nov 2012 | 1 |
| NCT01496469Hypertension · United States | 2 | Completed | Takeda | Aug 2014 | 121 |
| NCT01101035Cardiovascular Diseases · United States, Mexico | 3 | Completed | Takeda | May 15, 2017 | 6,198 |
| NCT01082640Renal Insufficiency · United States | 2 | Completed | Takeda | May 2012 | 96 |
| NCT01078389Gout · United States | 2 | Completed | Takeda | Sep 2013 | 314 |
| NCT01077284Kidney Calculi · United States | 2 | Completed | Takeda | Nov 2011 | 99 |
| NCT00821392Gout | 3 | Completed | SK Chemicals | Sep 2007 | 181 |
| NCT00430248Gout · United States | 3 | Completed | Takeda | Mar 2008 | 2,269 |
| NCT00175019Gout | 3 | Completed | Takeda | Feb 2007 | 1,086 |
| NCT00174941Gout | 2 | Completed | Takeda | Dec 2006 | 116 |
| NCT00174967Gout | 2 | Completed | Takeda | Jul 2001 | 153 |
| NCT00174915Gout | 3 | Completed | Takeda | Apr 2004 | 1,072 |
| NCT00102440Gout | 3 | Completed | Takeda | Feb 2004 | 760 |
How it is read
Names in the registry
- “Febuxostat”, 32 entries
- “Febuxostat XR”, 4 entries
- “Febuxostat 40 mg”, 3 entries
- “Febuxostat 80 mg”, 2 entries
- “SHR4640 ; Febuxostat”, 1 entry
Conditions, from the studies’ own filings
- Gout, 19 studies
- Hyperuricemia, 3 studies
- Tumor Lysis Syndrome, 2 studies
- Polycystic Kidney, Autosomal Dominant, 1 study
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.